FDA accepts Regeneron filing to widen use of Eylea

The FDA has accepted Regeneron's (REGN +3.3%) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion, a common vascular disease among the elderly that is caused by a blockage of one of the small veins that carry blood away from the retina.

Regeneron's application follows a successful Phase III trial.

Eylea has already been authorized for other indications, including wet age-related macular edema.

From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (697) | Send Message
    This is absurd: ACTC, a $0.07 stock with a $200m market cap, has a *cure* for the conditions Eylea can merely *treat*in *smoe* patients. Eylea is literally a dead drug walking, and the public can't get enough of "short of the century" REGN.


    It's almost midnight for "Cinderella" stock REGN.
    25 Feb 2014, 12:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs